iBio, Inc. (IBIO) research
iBio, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.13
- As of
iBio, Inc. (IBIO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for IBIO. Method and limitations.
Share the IBIO intelligence card
See the full IBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the IBIO dossierActive signals for IBIO
- mediumEARNINGS_MISS
Q4-2026: Missed consensus by 7.7%, EPS $-0.07 vs $-0.065 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +949% to IBIO (2026Q2)
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in IBIO
- mediumEARNINGS_BEAT
Q3-2026: Beat consensus by 6.1% - EPS $-0.06 vs $-0.0639 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 31.6% - EPS $-0.49 vs $-0.3723 estimate
FREE, NO ACCOUNT
Every signal on IBIO, as it fires
You are seeing 5 of 8 signals recorded on IBIO since 2026-05-26.
The five above landed across 5 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 451033708 · 2026Q2 | $2.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 451033708 · 2026Q2 | $2.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 451033708 · 2026Q2 | $701K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 451033708 · 2026Q2 | $355K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IBIO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IBIO against its peers
IBIO's operating margin of -35141.0% ranks in the 21st percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | IBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 100000 USD | 500000 USD | 41 | 15 |
| Operating margin | -35141.0% | -5743.5% | 21 | 11 |
| Net margin | -33044.0% | -5570.6% | 21 | 11 |
| Return on equity | -38.6% | -110.4% | 78 | 19 |
Peers (23): CNTB, ANVS, MREO, BOLD, ACET, XLO, AURX, EXOZ, HYPD, PDSB, INMB, INKT, RNTX, IMA, GUTS, ELOX, XBIT, SER, HRTX, ELTX, KLRS, CSBR, SPRO. Left out: HYFT (period gap), ATHE (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (IBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IBIO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IBIOand get the insider, 13F, options, and confluence read in one view.